



Peginterferon/Ribavirin-Experienced, Genotype 4 Patients With Compensated Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:

Peginterferon/Ribavirin-Experienced, Genotype 4 Patients With Compensated Cirrhosis^a

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients who experienced virologic relapse after prior peginterferon/ribavirin therapy ^b	12 weeks	IIa, B
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^c	12 weeks	IIa, B
ALTERNATIVE	DURATION	RATING 
Daily ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin	12 weeks	IIa, B

^a For [decompensated cirrhosis](#), please refer to the appropriate section.

^b If the type of prior treatment failure (relapse vs breakthrough/nonresponse) is unknown, another recommended regimen should be used.

^c Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: November 6, 2019